Thalidomide and Thalidomide Analogues for Maintenance of Remission in Crohn's Disease

Overview

Journal Cochrane Database Syst Rev

Publisher Wiley

Specialties General Medicine
Health Services

Date 2009 Apr 17

PMID 19370685

Citations 6

Authors

Anthony K Akobeng

Pieter C Stokkers

Affiliations

Soon will be listed here.

Abstract

Background: Maintenance of remission is a major issue in the management of Crohn's disease. Thalidomide, a tumour necrosis factor-alpha (TNF-alpha) inhibitor and its analogue, lenalidomide, may have a role in the management of Crohn's disease, but it is not clear whether it is an effective maintenance therapy.

Objectives: To conduct a systematic review to evaluate the efficacy and safety of thalidomide and lenalidomide for the maintenance of remission in Crohn's disease.

Search Strategy: MEDLINE (1966 to September 2008), EMBASE (1984 to September 2008), the Cochrane Central Register of Controlled Trials from the Cochrane Library (Issue 3, 2008) and the IBD/FBD Review Group Specialized Trials Register were searched to identify relevant studies.

Selection Criteria: Randomised controlled trials which compared thalidomide with either placebo or an active comparator were considered for inclusion.

Data Collection And Analysis: No trials met the inclusion criteria.

Main Results: No studies that satisfied the inclusion criteria were found. In the absence of any suitable randomised controlled trial in this area, no analysis was performed.

Authors' Conclusions: There is no evidence to support or refute the use of thalidomide or its analogue, lenalidomide, as maintenance therapy for patients with Crohn's disease. Given the teratogenic nature of thalidomide its use for maintenance therapy is difficult to justify. Well designed clinical trials are needed to evaluate the efficacy and safety of lenalidomide in Crohn's disease and its use is not recommended until these data are available.

Citing Articles

Design, synthesis, and biological evaluation of novel bioactive thalidomide analogs as anticancer immunomodulatory agents.

Kotb A, Bakhotmah D, Abdallah A, Elkady H, Taghour M, Eissa I RSC Adv. 2022; 12(52):33525-33539.

PMID: 36505721 PMC: 9680624. DOI: 10.1039/d2ra06188k.

It's What's Up Front That Counts-Part Two: Esophageal Crohn's Disease Complicated by Recurrent Upper Gastrointestinal Bleeding.

Levy A, Ali N, Andrici J, Hamilton M Dig Dis Sci. 2019; 64(12):3446-3450.

PMID: 31677072 DOI: 10.1007/s10620-019-05922-x.

Treatment and outcomes: medical and surgical treatment for intestinal Behçet's disease.

Hisamatsu T, Hayashida M Intest Res. 2017; 15(3):318-327.

PMID: 28670228 PMC: 5478756. DOI: 10.5217/ir.2017.15.3.318.

Thalidomide for inflammatory bowel disease: Systematic review.

Bramuzzo M, Ventura A, Martelossi S, Lazzerini M Medicine (Baltimore). 2016; 95(30):e4239.

PMID: 27472695 PMC: 5265832. DOI: 10.1097/MD.0000000000004239.

Inflammatory bowel diseases and human reproduction: a comprehensive evidence-based review.

Palomba S, Sereni G, Falbo A, Beltrami M, Lombardini S, Boni M World J Gastroenterol. 2014; 20(23):7123-36.

PMID: 24966584 PMC: 4064059. DOI: 10.3748/wjg.v20.i23.7123.

References

Ehrenpreis E, Kane S, Cohen L, Cohen R, Hanauer S . Thalidomide therapy for patients with refractory Crohn's disease: an open-label trial. Gastroenterology. 1999; 117(6):1271-7. DOI: 10.1016/s0016-5085(99)70276-3. View

Bariol C, Meagher A, Vickers C, Byrnes D, Edwards P, Hing M . Early studies on the safety and efficacy of thalidomide for symptomatic inflammatory bowel disease. J Gastroenterol Hepatol. 2002; 17(2):135-9. DOI: 10.1046/j.1440-1746.2002.02564.x. View

Bauditz J, Wedel S, Lochs H . Thalidomide reduces tumour necrosis factor alpha and interleukin 12 production in patients with chronic active Crohn's disease. Gut. 2002; 50(2):196-200. PMC: 1773116. DOI: 10.1136/gut.50.2.196. View

Meierhofer C, Dunzendorfer S, Wiedermann C . Protein kinase C-dependent effects on leukocyte migration of thalidomide. J Infect Dis. 1999; 180(1):216-9. DOI: 10.1086/314842. View

Hanauer S, Feagan B, Lichtenstein G, Mayer L, Schreiber S, Colombel J . Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 2002; 359(9317):1541-9. DOI: 10.1016/S0140-6736(02)08512-4. View

Kane S, Stone L, Ehrenpreis E . Thalidomide as "salvage" therapy for patients with delayed hypersensitivity response to infliximab: a case series. J Clin Gastroenterol. 2002; 35(2):149-50. DOI: 10.1097/00004836-200208000-00006. View

Sandborn W, Hanauer S, Rutgeerts P, Fedorak R, Lukas M, MacIntosh D . Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut. 2007; 56(9):1232-9. PMC: 2701613. DOI: 10.1136/gut.2006.106781. View

Sands B, Anderson F, Bernstein C, Chey W, Feagan B, Fedorak R . Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med. 2004; 350(9):876-85. DOI: 10.1056/NEJMoa030815. View

Sands B, Podolsky D . New life in a sleeper: thalidomide and Crohn's disease. Gastroenterology. 1999; 117(6):1485-8. DOI: 10.1016/s0016-5085(99)70299-4. View

10.

Vasiliauskas E, Kam L, Hassard P, Papadakis K, Yang H, Zeldis J . An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's disease. Gastroenterology. 1999; 117(6):1278-87. DOI: 10.1016/s0016-5085(99)70277-5. View

11.

Schreiber S, Khaliq-Kareemi M, Lawrance I, Thomsen O, Hanauer S, McColm J . Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med. 2007; 357(3):239-50. DOI: 10.1056/NEJMoa062897. View

12.

Colombel J, Sandborn W, Rutgeerts P, Enns R, Hanauer S, Panaccione R . Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology. 2007; 132(1):52-65. DOI: 10.1053/j.gastro.2006.11.041. View

13.

Jadad A, Moore R, Carroll D, Jenkinson C, Reynolds D, Gavaghan D . Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials. 1996; 17(1):1-12. DOI: 10.1016/0197-2456(95)00134-4. View

14.

Meierhofer C, Wiedermann C . New insights into the pharmacological and toxicological effects of thalidomide. Curr Opin Drug Discov Devel. 2003; 6(1):92-9. View

15.

Sabate J, Villarejo J, Lemann M, Bonnet J, Allez M, Modigliani R . An open-label study of thalidomide for maintenance therapy in responders to infliximab in chronically active and fistulizing refractory Crohn's disease. Aliment Pharmacol Ther. 2002; 16(6):1117-24. DOI: 10.1046/j.1365-2036.2002.01273.x. View

16.

Plamondon S, Ng S, Kamm M . Thalidomide in luminal and fistulizing Crohn's disease resistant to standard therapies. Aliment Pharmacol Ther. 2007; 25(5):557-67. DOI: 10.1111/j.1365-2036.2006.03239.x. View

17.

Rutgeerts P, DHaens G, Targan S, Vasiliauskas E, Hanauer S, Present D . Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology. 1999; 117(4):761-9. DOI: 10.1016/s0016-5085(99)70332-x. View